U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287930) titled 'A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia' on Dec. 04.
Brief Summary: This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 STAR-T cell therapy in patients with autoimmune hemolytic anemia who have failed >=3 lines of therapy. The objective is to evaluate the safety, preliminary efficacy, pharmacokinetics/pharmacodynamics (PK/PD), and immune cell reconstitution characteristics of YTS109 cell therapy in Multi-rAIHA subjects who have faile...